News
The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it ...
Stanford University researchers developed a machine learning-based method capable of diagnosing multiple diseases using B cell and T cell receptor sequences. The model, called Machine learning for ...
A Northwestern Medicine study has uncovered new insights that may aid in understanding and potentially treating one of the ...
In two new studies, scientists at Oregon Health & Science University have uncovered detailed blueprints of how certain ...
Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...
CAR T-cell therapy is a pivotal growth area in oncology, driven by advances in gene editing, diversification of clinical use ...
A new artificial intelligence (AI) tool can simultaneously assess blood samples for infections, autoimmune diseases, and vaccine responses, according to a new study. The algorithm analyzed genes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback